

Product Data Sheet

Product Name: EIDD-2801

Cat. No.: GC18413

Chemical Properties

Cas. No. 2349386-89-4

Chemical Name Uridine, 4-oxime, 5'-(2-methylpropanoate)

SMILES O[C@@H]([C@H]([C@H](N1C(N/C(C=C1)=N/O)=O)O2)O)[C@H]2COC(C(C)C)=O


Formula $C_{13}H_{19}N_3O_7$ M.Wt 329.31

Solubility 100 mg/mL in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

EIDD-2801 (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease^[1].

EIDD-2801 (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever^[2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal Model: C57BL/6 mice (intranasal infection with SARS-CoV) [1]

Dosage: 50, 150, 500 mg/kg

Administration: Oral; every 12 hours for 3 days

Result: Body weight loss is significantly diminished or prevented.

Animal Model: Ca/09-infected female ferrets [1]

Dosage: 7 mg/kg

Administration: Oral; twice daily for 3.5 days

Result: Shed virus load and duration of fever were significantly reduced.

Background

EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment.

Reference:

[1]. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci Transl Med*. 2020 Apr 6. pii: eabb5883.

[2]. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. *Sci Transl Med*. 2019 Oct 23;11(515). pii: eaax5866.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA